Morgan Stanley Neuro Metrix, Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$1.36 - $22.72 $3,091 - $51,642	2,273 Added 75766.67%	2,276 $3,000
Q3 2022 Nov 14, 2022	SELL	$2.97 - $23.6 $436 - $3,469	-147 Reduced 98.0%	3 $0
Q2 2022 Oct 27, 2022	SELL	$2.81 - $5.5 $843 - $1,650	-300 Reduced 66.67%	150 $1,000
Q2 2022 Aug 15, 2022	SELL	$2.81 - $5.5 $843 - $1,650	-300 Reduced 66.67%	150 $1,000
Q1 2022 Oct 27, 2022	BUY	$3.42 - $6.37 $1,026 - $1,911	300 Added 200.0%	450 $2,000
Q1 2022 May 13, 2022	SELL	$3.42 - $6.37 $46,717 - $87,014	-13,660 Reduced 96.81%	450 $2,000
Q4 2021 Feb 14, 2022	BUY	$5.02 - $9.82 $66,314 - $129,722	13,210 Added 1467.78%	14,110 $70,000
Q3 2021 Nov 15, 2021	BUY	$3.23 - $24.73 $2,907 - $22,257	900 New	900 $9,000

320

Ticker NURO
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 7,757,230
Market Cap $30.3M
Description
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to e...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.